Thalassaemia care is advancing fast, from gene therapies to AI diagnostics, but access and prevention still lag behind. Hear from the authors of The Lancet Haematology's "Thalassaemia revisited: from health burden to breakthroughs" Series, produced with The Lancet Regional Health – Southeast Asia, on epidemiology across Asia, what's working in prevention, the real barriers to gene therapy access, and what's next for hydroxyurea, regional manufacturing, and AI in patient care.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Lancet Group. Innehållet i podden är skapat av The Lancet Group och inte av,
eller tillsammans med, Poddtoppen.